The Motley Fool

2 stocks I’d buy and hold for the next 20 years

Image source: Getty Images.

Suppose you were offered some cash to invest in just two stocks, with the condition that you had to keep them for 20 years no matter what happened. What would you choose?

That’s a tough one. Even Warren Buffett, renowned for his recommendation that if you wouldn’t own a company for ten years you shouldn’t own it for a minute, allows for selling if things start to turn sour. But I’ll have a go.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Insurance safety

I’ve always liked the insurance sector and have invested in it on and off for years. For a 20-year, no-sell pick I’d be tempted by Prudential purely for its safety — it’s the most conservatively managed insurance firm I can think of.

But I see the whole sector as far safer now that it’s been chastened by the financial crisis, and I think I’d actually go for Legal & General Group (LSE: LGEN).

Legal & General is nicely diversified as an insurer, being in the life business but also with plenty of exposure to the long-term savings and investment management segment, both of which help offset any risks from its general insurance activities.

The firm is a very solid dividend payer too, with forecast yields reaching more than 6% by 2019 — and we’ve seen steady progressive rises over the past five years in line with growth in earnings per share.

With a 20-year horizon, short-term valuation really doesn’t matter a great deal. But in plumping for Legal & General, I wouldn’t even be having to swallow a highly valued share price.

No, we’re looking at a forward P/E of only around 10.5, dropping to 9.6 on 2016 forecasts, which I think is cheap now. The only valuation downside is that the shares trade for around 2.3 times net asset value, but with the firm’s diversification across insurance segments, I’m not too worried.

Popping pills

For my next choice I considered utilities companies, but who knows what could happen to regulated industries over the next 20 years, especially if Jeremy Corbyn should gain power and try to nationalise the sector.

Instead I’m going to go for what might seem like a surprise choice in GlaxoSmithKline (LSE: GSK). Now, I know it’s been erratic, it’s at the mercy of the copycats when drug patents expire, and it needs a constantly renewed development pipeline simply to stand still. And it’s always at risk of upstarts with new technology turning the old pills and potions approach into history.

But over the next 20 years we’re going to see a vastly bigger proportion of the world’s population finding themselves in improved economic conditions and demanding more and more healthcare.

And there are so many medical conditions still around for which we only have barely adequate treatments at best that there’s always going to be a need for the high-powered research that only the world’s top pharmaceuticals companies can afford.

New technologies and uppity startups? They’ll still need big funding, and the likes of Glaxo are ideally place to partner them or simply buy them out.

Finally, as it happens, I also think Glaxo is on a pretty reasonable valuation even now, on forward P/E multiples of a bit over 13, and with expected dividend yields of 5.6%.

My colleague Harvey Jones recent tipped GlaxoSmithKline as his buy of the decade. Make that two.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.